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Abstract
The 8th NCRI Cancer Conference took place from 4th until 7th of November 2012 in the BT Convention Centre, 
Liverpool, UK. This scientific event has established itself as the leading international oncology meeting in the 
UK and this year attracted more than 2,000 delegates: from researchers and data managers to clinicians, nurses 
and policy makers. The conference covered six main topics: 1) Diagnosis and therapy 2) Epidemiology and 
prevention 3) Information, patients and the public 4) Survivorship and end-of-life care 4) The cancer cell and 
model systems 6) Tumour specific research. This report presents the highlights of the conference.
BioDiscovery was represented at the conference by its 
Editor-in-Chief, Managing Editor, Head of Editorial 
Office and Assistant Editor who gave talks, presented 
posters and interviewed delegates (see supplemental 
video).
Cancer Research UK Lifetime Achievement in 
Cancer Research Prize
The highlight of the conference was the Cancer Research 
UK Prize ceremony. Professor Sir David Lane received 
the Cancer Research UK Lifetime Achievement in 
Cancer Research Prize (Figure 1). As we have written 
about before, the monumental discovery of the tumour 
suppressor molecule p53 by Sir David revolutionised our 
understanding of how cancer cells grow and divide [1].
In his presentation to mark the award, Professor 
Lane looked back on his career so far. David did his 
PhD in immunology with Professor Avrion Mitchison 
in University College London and his first post-doc in 
the laboratories of the Imperial Cancer Research Fund 
working with Lionel Crawford. At that time he discovered 
p53, a protein that interacts with the Large T antigen, 
and hypothesised that this protein might be involved 
in control of cell growth [2]. Later Dr Lane joined the 
Figure 1. Professor Sir David Lane with the Cancer Research 
UK Lifetime Achievement in Cancer Research Prize.
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Cold Spring Harbor Laboratory where he started writing 
the book “Antibodies: A Laboratory Manual” published 
in 1988 [3], which became one of the most successful 
practical guides in biomedicine. After returning to the 
UK, David set up his own laboratory with CRC funding 
at Imperial College London, then moved to the ICRF 
laboratories at Clare Hall and in 1990 moved to Dundee 
to help establish the CRC laboratories. In 1996 Professor 
Lane founded the biopharmaceutical company Cyclacel 
Ltd and pioneered the use of peptidomimetics as a 
tool for drug discovery [4-7]. Cyclacel has developed 
several compounds as cancer drug candidates, which 
are currently under clinical investigation [8]. Currently 
Professor Lane is the Chief Scientist of the Agency for 
Science, Technology and Research (A*STAR) and the 
Director of the p53 Lab.
In his plenary lecture Professor Lane also shared his 
vision of the future in which he believes scientists will 
be able to “drug the undruggable” molecules, which are 
involved in many cancers, but have proven stubbornly 
difficult to target with drugs. Moreover, he outlined recent 
work in targeting ‘undruggable’ targets such as p53, Myc 
and Ras. In addition, Professor Lane presented exciting 
novel discovery methods such as the development of 
molecules called “stapled peptides”. ”Stapled peptides” 
are stabilised peptides, which show exquisite specificity 
and ability to resist degradation, while acting in a drug-
like manner. 
Targeting myeloma cells and their 
microenvironment
Professor Kenneth Anderson, a world-leading expert in 
myeloma from the Harvard Medical School, presented 
data showing how survival from multiple myeloma 
has increased over the last decades due to advances in 
treatment and new drugs such as bortezomib (Velcade) 
and lenalidomide (Revlimid). Professor Anderson 
argued that new rationally-based combination therapies 
are essential to the treatment of refractory multiple 
myeloma. He also suggested that targeting the tumour in 
its microenvironment and development of personalised 
therapies are the approaches that could bring forward a 
real prospect of long-term survival for myeloma patients.
Clinical cancer genetics in the era of personalised 
cancer medicine
Professor Judy Garber form Dana-Farber Cancer 
Institute, Boston discussed how fast-developing DNA 
sequencing technologies and the reduced cost of whole 
genome analysis present scientists and clinicians with 
the opportunity to develop and implement systems that 
incorporate cancer genomics into practice. Professor 
Garber also discussed the ethical issues and challenges 
posed by genetic sequencing.
Targeting the CRKL/Src family kinases in 
rhabdomyosarcoma
Dr Lee Helman from the US National Cancer Institute 
talked about the advancement in understanding 
rhabdomyosarcoma – the most common soft tissue 
sarcoma of childhood. His team has identified novel 
signalling pathways involved in rhabdomyosarcoma 
survival. Key proteins in these pathways are CRKL 
and IGFR1. Dr Helman presented data demonstrating 
that dasatinib is able to inhibit the CRKL pathway and 
suppress the growth of tumour cells in vitro and in vivo. 
In addition he stated that inhibition of the two non-
overlapping IGFR1 and CRKL pathways simultaneously 
by a combination of IGFIR Ab and dasatinib enhances 
the overall tumour growth inhibition. Ongoing 
experiments in mice have also shown the same results 
and, if confirmed, will lead to clinical trials. 
Cancer evolution
Several very interesting and provocative lectures 
concerning cancer evolution were presented in a session 
chaired by Professor Gerard Evan. He talked about the 
need to “de-mystify and de-mythologise” cancer, thus 
removing some of the misconceptions about the disease. 
“It is important to understand” Professor Evan said 
“Cancer is not a single, unitary thing, but a phenomenon 
that constantly changes and evolves.” This is the main 
reason why some cancer treatments can effectively kill 
tumour cells, but fail to extend life. Molecular evolution 
allows the remaining cancer cells to “re-wire signalling 
networks” and evolve ways to resist treatment and grow 
again. Several other speakers also discussed the need to 
use evolutionary biology tools to better understand how 
cancer grows, which will eventually lead to improved 
treatment and prevention of the disease. Professor Carlo 
Maley from the University of California discussed how a 
tumour’s genetic diversity affects its response to treatment. 
He suggested that cancer prevention strategies that reduce 
the rate of genetic mutation should be exploited. Professor 
Maley argued that a successful anti-cancer strategy 
must maintain a stable, non-growing tumour, as killing 
tumour cells with drugs could inadvertently allow drug-
resistant cells to grow faster. In his lecture Professor Mel 
Greaves from the Institute of Cancer Research also gave 
evidence supporting the idea of cancer’s evolutionary 
nature. Professor Greaves showed proof that leukaemias 
are actually a collection of sub-clones, all existing within 
the same patient. Finally, Professor Peter Campbell, 
from the world-leading Wellcome Trust Sanger Institute 
in Cambridge, outlined the idea that cancer evolves 
dynamically, as clonal expansions supersede or overlap one 
another, driven by shifting selective pressures, mutation 
processes and disturbed cancer genes. He suggested that 
applying complex maths and statistics to detailed genetic 
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analyses can help the reconstruction of tumours’ histories 
and provide insights into mutational processes, cellular 
repair pathways and networks associated with cancer 
development.
Breast cancer
Many plenary lectures and discussions were devoted to all 
aspects of breast cancer. The NCRI chief executive Harpal 
Kumar, presented the results of the recent Independent 
Breast Screening Review. Professor Sir Michael Marmot 
from the Institute of Health Equity, University College 
London also discussed the breast screening review. 
He chairs an independent panel which will carry out 
a rigorous review of the evidence of breast screening’s 
benefits and harms. The main harm of screening which the 
panel looked at was that of overdiagnosis. In addition, the 
leading US cancer researcher Professor Joan Massagué 
from the Memorial Sloan-Kettering Cancer Center 
discussed the latest concept of how breast cancers spread; 
why some breast cancers spread to the bone, whereas 
others spread to the lungs. Professor Massagué argued 
that a better understanding of these mechanisms will help 
the development of treatments to eradicate disseminated 
tumour cells and prevent metastasis. 
Prostate cancer
Dr Robert Bristow, a prostate cancer expert from the 
Ontario Cancer Institute, Princess Margaret Hospital in 
Toronto discussed personalised genomic approaches and 
pathway identification for individualised prostate cancer 
therapy. According to Dr Bristow men with prostate cancer 
can be divided into three groups: low, intermediate and 
high risk. Low risk men have slow-growing tumours that 
do not need immediate treatment but should be monitored. 
Intermediate risk men have cancers which are growing but 
not spreading and are usually treated with surgery and/
or radiotherapy. High risk men have aggressive, invasive 
cancers that need urgent, intensive treatment. Up to 40% 
of patients with intermediate-risk prostate cancer will fail 
prostatectomy or precision image-guided radiotherapy. Dr 
Bristow’s research focused on identification of additional 
genetic prognosticators for stratification patients towards 
intensified combination therapy. Dr Bristow’s team have 
shown that men with intermediate risk prostate cancer can 
be divided into four groups according to their respond to 
treatment. His team is working together with scientists at 
The Institute of Cancer Research in Surrey to analyse the 
DNA pattern(s) of prostate tumours. Primary data suggests 
that the use of personalised genomics may improve the 
clinical outcome for the patient. 
Can aspirin prevent cancer?
The question about aspirin’s potential role in preventing 
cancer was discussed in one of the sessions. Strong 
evidence was presented that taking regular aspirin could 
reduce the risk of some cancers, especially bowel cancer. 
Participants debated whether people should take aspirin, 
and if so, who would most likely benefit from it given 
aspirin’s serious side effects like internal bleeding. 
Professor Sir John Burn from Newcastle University 
reported results from a study involving 937 Lynch 
syndrome patients which showed 60% fewer cancers 
in patients taking aspirin. Professor Burn research also 
suggests that aspirin is beneficial for people at high risk 
of colorectal cancer. 
Conclusion
The 8th NCRI Cancer Conference provided an opportunity 
for participants representing the whole field of oncology 
(from researchers and data managers to clinicians, nurses 
and policy makers) to present their data and to establish 
trans-disciplinary collaborations. 
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